Concepedia

Sukrut Shah

SS

51

Publications

7.6K

Citations

27

H-Index

1994

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

National Cancer Center Hospital East

Yonsei University

Samsung Medical Center

Cornell University

Sukrut Shah is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacotherapy, and pharmacology.

Top concepts

Publications per year

1994–2024

50

Publications

51

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun, Lin Shen, Manish A. Shah et al. · The Lancet · 2021 · 1.5K citations · Full text

, , +8

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer

Kohei Shitara, Eric Van Cutsem, Yung‐Jue Bang et al. · JAMA Oncology · 2020 · 1.1K citations · Full text

Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease

Christopher P. Cannon, Sukrut Shah, Hayes M. Dansky et al. · New England Journal of Medicine · 2010 · 746 citations · Full text

Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans

Thomas Sudhop, Dieter Lütjohann, Annette Kodal et al. · Circulation · 2002 · 677 citations

The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer

Yelena Y. Janjigian, Akihito Kawazoe, Patricio Yañez et al. · Nature · 2021 · 648 citations · Full text

, , +9

Rows per page

1–5 of 51